A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Anthracyclines; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors EirGenix
- 02 May 2019 Planned End Date changed from 31 Jul 2021 to 13 Oct 2021.
- 29 Apr 2019 According to the EirGenix media release, the primary endpoint analysis is expected to be completed in the second half of 2020 to support registration.
- 02 Jan 2019 Planned End Date changed from 3 Sep 2021 to 31 Jul 2021.